Effectiveness of a Short Duration of Neoadjuvant Endocrine Therapy in Patients with HR+ Breast Cancer—An NCDB Analysis (2004–2016)

BACKGROUND: National medical/surgical organizations have recommended the use of neoadjuvant endocrine therapy (NET) to bridge surgery delay of weeks to months for patients with hormone receptor positive (HR+) breast cancer during the ongoing coronavirus disease 2019 (COVID-19) pandemic. The effects...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Surg Oncol
Autors principals: Goldbach, Macy M., Burkbauer, Laura, Bharani, Tina, Williams, Austin D., Keele, Luke, Rothman, Jami, Jankowitz, Rachel, Tchou, Julia C.
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2021
Matèries:
Breast Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8202052/
https://ncbi.nlm.nih.gov/pubmed/34125350
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-021-10287-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars